The Evolution of Pneumococcal Vaccine and Vaccine Schedule in the USA: A Narrative Review of the Last Two Decades (2003-2023) — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
The Evolution of Pneumococcal Vaccine and Vaccine Schedule in the USA: A Narrative Review of the Last Two Decades (2003-2023)
Department of Health Care Administration and Service Management, Conestoga College, Kitchener, Canada
,
Department of Obstetrics and Gynecology, Kenechukwu Specialist Hospital and Maternity, Enugu, Nigeria
,
Department of Family Medicine, Larkin Community Hospital Palm Springs Campus, Miami, USA
,
Department of Internal Medicine, University of Alberta Hospital, Edmonton, Canada
1 Department of Health Care Administration and Service Management, Conestoga College, Kitchener, Canada
2 Department of Obstetrics and Gynecology, Kenechukwu Specialist Hospital and Maternity, Enugu, Nigeria
3 Department of Family Medicine, Larkin Community Hospital Palm Springs Campus, Miami, USA
4 Department of Internal Medicine, University of Alberta Hospital, Edmonton, Canada
Streptococcus pneumoniae is a known notorious cause of invasive pneumococcal diseases as well as asymptomatic host carriage. Efforts have been made to curb this infectious organism through various vaccine strategies. However, its several strains and serotypes have necessitated various vaccine schedules and updates in the USA and globally. The evolution in pneumococcal vaccine schedules is not without challenges, such as cost, vaccine hesitancy, uptake and global disparities. This narrative review synopsizes the history of the Pneumococcal Vaccine and changes in its schedules in the last two decades based on published data. We focused on the impact of pneumococcal vaccination on invasive pneumococcal diseases, historical limitations, current challenges and future directions. Despite advancements in vaccination against S. pneumoniae infections, some pertinent issues exist that need to be swiftly fixed, to reduce national and thus global burden of pneumococcal diseases.
Gierke, R., Wodi, A.P. and Kobayashi, M. (2021) Pneumococcal Disease. In: Hall, E., Wodi, A.P., Hamborsky, J., Morelli, V., Schillie, S., Eds., Epidemiology and Preven tion of Vaccine-Preventable Diseases , 14th Edition, Public Health Foundation, 255-274.
Noharet-Koenig, R., Lasota, K., Faivre, P. and Langevin, E. (2023) Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States. MDM Policy & Practice , 8. https://doi.org/10.1177/23814683231174432
World Health Organization (2019) WHO Position Paper: Pneumococcal Conjugate Vaccines in Infants and Children under 5 Years of Age. Weekly Epidemiological Record , 8, 85-104. https://www.who.int/publications/i/item/10665-310968
Musher, D.M., Anderson, R. and Feldman, C. (2022) The Remarkable History of Pneumococcal Vaccination: An Ongoing Challenge. Pneumonia , 14, Article No. 5. https://doi.org/10.1186/s41479-022-00097-y
Wodi, A.P. and Morelli, V. (2021) Principles of Vaccination. In: Hall, E., Wodi, A.P., Hamborsky, J., Morelli, V., Schillie, S., Eds., Epidemiology and Prevention of Vaccine-Preventable Diseases , 14th Edition, Public Health Foundation, 1-8. https://www.cdc.gov/vaccines/pubs/pinkbook/prinvac.html
Savoy, M.L. (2024) Pneumococcal Vaccine. Merck & Co., Inc., Rahway Center for Disease Control.
Centers for Disease Control and Prevention (2008) Progress in Introduction of Pneumococcal Conjugate Vaccine—Worldwide, 2000-2008. Morbidity and Mortality Weekly Report , 57, 1148-1151. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5742a2.htm
Chang, Q., Stevenson, A.E., Croucher, N.J., Lee, G.M., Pelton, S.I., Lipsitch, M., et al . (2015) Stability of the Pneumococcal Population Structure in Massachusetts as PCV13 Was Introduced. BMC Infectious Diseases , 15, Article No. 68. https://doi.org/10.1186/s12879-015-0797-z
Tahamtan, A., Charostad, J., Hoseini Shokouh, S.J. and Barati, M. (2017) An Overview of History, Evolution, and Manufacturing of Various Generations of Vaccines. Journal of Archives in Military Medicine . In Press. https://doi.org/10.5812/jamm.12315
Westerink, M.A.J., Schroeder Jr, H.W. and Nahm, M.H. (2011) Immune Responses to Pneumococcal Vaccines in Children and Adults: Rationale for Age-Specific Vaccination. Aging and Disease , 3, 51-67.
Center for Disease Control (2024) About Pneumococcal Vaccines. https://www.cdc.gov/vaccines/vpd/pneumo/hcp/about-vaccine.html#print
Kobayashi, M., Farrar, J.L., Gierke, R., Britton, A., Childs, L., Leidner, A.J., et al . (2022) Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices—United States, 2022. Morbidity and Mortality Weekly Report , 71, 109-117. https://doi.org/10.15585/mmwr.mm7104a1
Rudawsky, N. and Mansukhani, R. (2022) The Evolution of Pneumococcal Vaccines and Current Guidelines. https://www.pharmacytimes.com/view/the-evolution-of-pneumococcal-vaccines-and-current-guidelines
Committee on Infectious Diseases (2010) Recommendations for the Prevention of Streptococcus pneumoniae Infections in Infants and Children: Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPSV23). Pediatrics , 126, 186-190. https://doi.org/10.1542/peds.2010-1280
Wasserman, M., Chapman, R., Lapidot, R., Sutton, K., Dillon-Murphy, D., Patel, S., et al . (2021) Twenty-year Public Health Impact of 7-and 13-Valent Pneumococcal Conjugate Vaccines in US Children. Emerging Infectious Diseases , 27, 1627-1636. https://doi.org/10.3201/eid2706.204238
Grijalva, C.G. and Pelton, S.I. (2011) A Second-Generation Pneumococcal Conjugate Vaccine for Prevention of Pneumococcal Diseases in Children. Current Opinion in Pediatrics , 23, 98-104. https://doi.org/10.1097/mop.0b013e328341d1f5
Micoli, F., Romano, M.R., Carboni, F., Adamo, R. and Berti, F. (2023) Strengths and Weaknesses of Pneumococcal Conjugate Vaccines. Glycoconjugate Journal , 40, 135-148. https://doi.org/10.1007/s10719-023-10100-3
U.S. Food and Drug Administration (2017) Package Insert-Prevnar 13-FDA. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert------Prevnar-13.pdf
Pichichero, M.E. (2017) Pneumococcal Whole-Cell and Protein-Based Vaccines: Changing the Paradigm. Expert Review of Vaccines , 16, 1181-1190. https://doi.org/10.1080/14760584.2017.1393335
Li, S., Liang, H., Zhao, S., Yang, X. and Guo, Z. (2023) Recent Progress in Pneumococcal Protein Vaccines. Frontiers in Immunology , 14, Article 1278346. https://doi.org/10.3389/fimmu.2023.1278346
McDaniel, L.S. and Swiatlo, E. (2021) If Not Now, When? Nonserotype Pneumococcal Protein Vaccines. Open Forum Infectious Diseases , 8, ofab576. https://doi.org/10.1093/ofid/ofab576
Duke, J.A. and Avci, F.Y. (2023) Emerging Vaccine Strategies against the Incessant Pneumococcal Disease. npj Vaccines , 8, Article No. 122. https://doi.org/10.1038/s41541-023-00715-w
Hammitt, L.L., Campbell, J.C., Borys, D., Weatherholtz, R.C., Reid, R., Goklish, N., et al . (2019) Efficacy, Safety and Immunogenicity of a Pneumococcal Protein-Based Vaccine Co-Administered with 13-Valent Pneumococcal Conjugate Vaccine against Acute Otitis Media in Young Children: A Phase IIb Randomized Study. Vaccine , 37, 7482-7492. https://doi.org/10.1016/j.vaccine.2019.09.076
Dunne, E.M., Nunes, M.C., Slack, M.P.E., Theilacker, C. and Gessner, B.D. (2023) Effects of Pneumococcal Conjugate Vaccines on Reducing the Risk of Respiratory Disease Associated with Coronavirus Infection. Pneumonia , 15, Article No. 10. https://doi.org/10.1186/s41479-023-00112-w
International Vaccine Access Center (IVAC) (n.d.) Johns Hopkins Bloomberg School of Public Health. Vaccine Introduction over Time. VIEW-Hub. https://view-hub.org/vaccine/pcv?set=vaccine-introduction-over-time&group=vaccine-introduction&category=pcv&year=2019
Conklin, L., Loo, J.D., Kirk, J., Fleming-Dutra, K.E., Deloria Knoll, M., Park, D.E., et al . (2014) Systematic Review of the Effect of Pneumococcal Conjugate Vaccine Dosing Schedules on Vaccine-Type Invasive Pneumococcal Disease among Young Children. Pediatric Infectious Disease Journal , 33, S109-S118. https://doi.org/10.1097/inf.0000000000000078
Mueller, K., Koury, J., Sarangarm, P., Hellinga, R.C., Shenk, E., Stewart, M.B., et al . (2023) Pneumococcal Polysaccharide Vaccination (PPSV23) in High-Risk Pediatric Patients with Diabetes. The Journal of Pediatric Pharmacology and Therapeutics , 28, 417-422. https://doi.org/10.5863/1551-6776-28.5.417
Committee on Infectious Diseases (2000) Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis. Pediatrics , 106, 362-366. https://doi.org/10.1542/peds.106.2.362
Esposito, S., Lizioli, A., Lastrico, A., Begliatti, E., Rognoni, A., Tagliabue, C., et al . (2007) Impact on Respiratory Tract Infections of Heptavalent Pneumococcal Conjugate Vaccine Administered at 3, 5 and 11 Months of Age. Respiratory Research , 8, Article No. 12. https://doi.org/10.1186/1465-9921-8-12
Kalin, M. (1998) Pneumococcal Serotypes and Their Clinical Relevance. Thorax , 53, 159-162. https://doi.org/10.1136/thx.53.3.159
Centers for Disease Control and Prevention (2024) Antibiotic-Resistant Streptococcus Pneumoniae. https://www.cdc.gov/pneumococcal/php/drug-resistance/index.html#:~:text=Vaccine%20impact&text=Pneumococcal%20conjugate%20vaccines%20(PCVs)%20include,IPD%20in%20the%20United%20States
van Heuvel, L., Paget, J., Dückers, M. and Caini, S. (2023) The Impact of Influenza and Pneumococcal Vaccination on Antibiotic Use: An Updated Systematic Review and Meta-Analysis. Antimicrobial Resistance & Infection Control , 12, Article No. 70. https://doi.org/10.1186/s13756-023-01272-6
Public Health Agency of Canada (2024) Pneumococcal Vaccines: Canadian Immunization Guide. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-16-pneumococcal-vaccine.html#t3
Public Health England (2019) Changes to the Infant Pneumococcal Conjugate Vaccine Schedule. PHE Publications. https://assets.publishing.service.gov.uk/media/5de5018940f0b650e4a64d50/PCV_schedule_change_HCP_information.pdf
Bloom, D.E., Kirby, P.N., Pugh, S. and Stawasz, A. (2020) Commentary: Why Has Uptake of Pneumococcal Vaccines for Children Been So Slow? the Perils of Undervaluation. Pediatric Infectious Disease Journal , 39, 145-156. https://doi.org/10.1097/inf.0000000000002521
World Health Organization (n.d.) Pneumococcal Vaccination Coverage. https://immunizationdata.who.int/pages/coverage/PCV.html?CODE=Global&ANTIGEN=PCV3&YEAR=
World Health Organization: Department of Immunization, Vaccines and Biologicals. (2014) A Call-to-Action for National Programmes and the Global Community by the WHO Immunization Practices Advisory Committee, Geneva, Switzerland. https://iris.who.int/bitstream/handle/10665/131568/WHO_IVB_14.05_eng.pdf?sequence=1
Lane, S., MacDonald, N.E., Marti, M. and Dumolard, L. (2018) Vaccine Hesitancy around the Globe: Analysis of Three Years of WHO/UNICEF Joint Reporting Form Data-2015-2017. Vaccine , 36, 3861-3867. https://doi.org/10.1016/j.vaccine.2018.03.063
Tricarico, S., McNeil, H.C., Cleary, D.W., Head, M.G., Lim, V., Yap, I.K.S., et al . (2017) Pneumococcal Conjugate Vaccine Implementation in Middle-Income Countries. Pneumonia , 9, Article No. 6. https://doi.org/10.1186/s41479-017-0030-5
Médecins Sans Frontières (2017) A Fair Shot for Vaccine Affordability: Understanding and Addressing the Effects of Patents on Access to Newer Vaccines. MSF Report. https://www.msfaccess.org/fair-shot-vaccine-affordability
Cai, F.Y., Fussell, T., Cobey, S. and Lipsitch, M. (2018) Use of an Individual-Based Model of Pneumococcal Carriage for Planning a Randomized Trial of a Whole-Cell Vaccine. PLOS Computational Biology , 14, e1006333. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6181404/ https://doi.org/10.1371/journal.pcbi.1006333
Patel, A.R., Breck, A.B. and Law, M.R. (2018) The Impact of Pharmacy-Based Immunization Services on the Likelihood of Immunization in the United States. Journal of the American Pharmacists Association , 58, 505-514.e2. https://doi.org/10.1016/j.japh.2018.05.011
Steyer, T.E., Ragucci, K.R., Pearson, W.S. and Mainous, A.G. (2004) The Role of Pharmacists in the Delivery of Influenza Vaccinations. Vaccine , 22, 1001-1006. https://doi.org/10.1016/j.vaccine.2003.08.045
de Koning, R., Gonzalez Utrilla, M., Spanaus, E., Moore, M. and Lomazzi, M. (2024) Strategies Used to Improve Vaccine Uptake among Healthcare Providers: A Systematic Review. Vaccine: X , 19, Article 100519. https://doi.org/10.1016/j.jvacx.2024.100519
Cataldi, J.R., Kerns, M.E. and O’Leary, S.T. (2020) Evidence-Based Strategies to Increase Vaccination Uptake: A Review. Current Opinion in Pediatrics , 32, 151-159. https://doi.org/10.1097/mop.0000000000000843
Centers for Disease Control and Prevention (CDC) (2013) Progress in Immunization Information Systems—United States, 2011. Morbidity and Mortality Weekly Report , 62, 48-51.